Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30136797 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTPIP4K2CALDH1A1L3MBTL1 | |
| SCHEMBL6670428 | 0.85 | ALDH1A1 (0.51) | SMN1; SMN2HTTPIP4K2CALDH1A1MEN1 | |
| SCHEMBL12377870 | 0.84 | L3MBTL1 (0.62) | SMN1; SMN2HTTPIP4K2CALDH1A1L3MBTL1 | |
| SCHEMBL4604449 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTPIP4K2CALDH1A1MEN1 | |
| SCHEMBL7452483 | 0.81 | ACLY (0.53) | SMN1; SMN2HTTALDH1A1L3MBTL1MEN1 | |
| SCHEMBL1092164 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTPIP4K2CALDH1A1L3MBTL1 | |
| SCHEMBL13226000 | 0.79 | CYP1A2 (0.54) | ALDH1A1L3MBTL1MEN1KMT2AHPGD | |
| SCHEMBL3375138 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2HTTPIP4K2CALDH1A1KMT2A | |
| SCHEMBL822762 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTALDH1A1L3MBTL1KMT2A | |
| SCHEMBL4607798 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | claimed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-12084434-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240076289-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | disclosed |
| WO-2002002525-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| US-5696110-A | ANTIULCER AGENTS | MERCK, SHARP & DOHME, LTD. (GB) | 1997-12-09 | — | — | US | disclosed |
| US-5663331-A | BACTERICIDES | IL-DONG PHARM. CO., LTD. (KR) | 1997-09-02 | — | — | US | disclosed |
| US-5650415-A | INHIBITORS OF CELL PROLIFERATION/DIFFERENTIATION, ANTITUMOR, ANTICANCER, TREATMENT OF FIBROTIC DISORDERS, BLOOD VESSEL PROLIFERATION | SUGEN, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| EP-0609306-A1 | BENZODIAZEPINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF CHOLECYSTOKININ AND/OR GASTRIN RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1994-08-10 | — | — | EP | disclosed |
| WO-1993008176-A1 | BENZODIAZEPINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF CHOLECYSTOKININ AND/OR GASTRIN RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1993-04-29 | — | — | WO | disclosed |
| EP-0539170-A1 | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors | MERCK SHARP & DOHME LTD. (GB) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | PIK3CA, PIK3CG, PIK3CD | SMN1; SMN2 3214/4885HTT 3054/4885PIP4K2C 23/4885 |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | SMN1; SMN2 3813/4885HTT 4574/4885PIP4K2C 1580/4885 |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | SMN1; SMN2 1130/4885HTT 2151/4885PIP4K2C 56/4885 |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | SMN1; SMN2 2109/4885HTT 3212/4885PIP4K2C 1829/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | SMN1; SMN2 1130/4885HTT 2151/4885PIP4K2C 56/4885 |
| US-20240076289-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | SMN1; SMN2 1130/4885HTT 2151/4885PIP4K2C 56/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | SMN1; SMN2 2109/4885HTT 3212/4885PIP4K2C 1829/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | SMN1; SMN2 1130/4885HTT 2151/4885PIP4K2C 56/4885 |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | SMN1; SMN2 1130/4885HTT 2151/4885PIP4K2C 56/4885 |
| US-12084434-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | SMN1; SMN2 1130/4885HTT 2151/4885PIP4K2C 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.